Literature DB >> 20132292

Characteristics of a large population of patients with refractory epilepsy attending tertiary referral centers in Italy.

Veriano Alexandre1, Giuseppe Capovilla, Cinzia Fattore, Valentina Franco, Antonio Gambardella, Renzo Guerrini, Francesca La Briola, Marianna Ladogana, Eleonora Rosati, Luigi Maria Specchio, Salvatore Striano, Emilio Perucca.   

Abstract

The characteristics of 1,124 consecutive adults and children with refractory epilepsy attending 11 tertiary referral centers in Italy were investigated at enrollment into a prospective observational study. Among 933 adults (age 16-86 years), the most common syndromes were symptomatic (43.7%) and cryptogenic (39.0%) focal epilepsies, followed by idiopathic (8.1%) and cryptogenic/symptomatic generalized (6.2%) epilepsies. The most common syndrome among 191 children was symptomatic focal epilepsy (35.1%), followed by cryptogenic focal (18.8%), cryptogenic/symptomatic generalized (18.3%), undetermined whether focal or generalized (16.8%), and idiopathic generalized (7.3%). Primarily and secondarily generalized tonic-clonic seizures were reported in 27.8% of adults and 16.8% of children. The most commonly reported etiologies were mesial temporal sclerosis (8.0%) and disorders of cortical development (6.2%) in adults, and disorders of cortical development (14.7%) and nonprogressive encephalopathies (6.8%) in children. More than three-fourths of subjects in both age groups were on antiepileptic drug (AED) polytherapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20132292     DOI: 10.1111/j.1528-1167.2009.02512.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  7 in total

Review 1.  Electro-clinical-pathological correlations in focal cortical dysplasia (FCD) at young ages.

Authors:  Hans Holthausen; Tom Pieper; Peter Winkler; Ingmar Bluemcke; Manfred Kudernatsch
Journal:  Childs Nerv Syst       Date:  2014-09-27       Impact factor: 1.475

2.  Off-label prescribing of antiepileptic drugs in pharmacoresistant epilepsy: a cross-sectional drug utilization study of tertiary care centers in Italy.

Authors:  Valentina Franco; Maria Paola Canevini; Giuseppe Capovilla; Giovambattista De Sarro; Carlo Andrea Galimberti; Giuliana Gatti; Renzo Guerrini; Angela La Neve; Eleonora Rosati; Luigi Maria Specchio; Salvatore Striano; Paolo Tinuper; Emilio Perucca
Journal:  CNS Drugs       Date:  2014-10       Impact factor: 5.749

3.  Long-term follow-up of a large cohort with focal epilepsy of unknown cause: deciphering their clinical and prognostic characteristics.

Authors:  Arife Çimen Atalar; Ebru Nur Vanlı-Yavuz; Ebru Yılmaz; Nerses Bebek; Betül Baykan
Journal:  J Neurol       Date:  2019-12-02       Impact factor: 4.849

4.  Systematic Adverse Drug Reaction Monitoring of Patients Under Newer Antiepileptic Drugs Using Routine Clinical Data of Inpatients.

Authors:  Annika Hilgers; Marion Schaefer
Journal:  Drugs Real World Outcomes       Date:  2016-05-25

5.  Validated outcome of treatment changes according to International League Against Epilepsy criteria in adults with drug-resistant focal epilepsy.

Authors:  Marco Mula; Gaetano Zaccara; Carlo Andrea Galimberti; Bruno Ferrò; Maria Paola Canevini; Addolorata Mascia; Oriano Mecarelli; Roberto Michelucci; Laura Rosa Pisani; Luigi Maria Specchio; Salvatore Striano; Emilio Perucca
Journal:  Epilepsia       Date:  2019-03-13       Impact factor: 5.864

6.  Incidence and prevalence of major epilepsy-associated brain lesions.

Authors:  Javier A López-Rivera; Victoria Smuk; Costin Leu; Gaelle Nasr; Deborah Vegh; Arthur Stefanski; Eduardo Pérez-Palma; Robyn Busch; Lara Jehi; Imad Najm; Ingmar Blümcke; Dennis Lal
Journal:  Epilepsy Behav Rep       Date:  2022-02-11

7.  Genetic generalized and focal epilepsy prevalence in the North American SUDEP Registry.

Authors:  Chloe Verducci; Daniel Friedman; Elizabeth Donner; Orrin Devinsky
Journal:  Neurology       Date:  2020-03-26       Impact factor: 9.910

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.